NCT03279692 2026-01-29
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
Massachusetts General Hospital
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT04659811 2025-04-17
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
University of California, San Francisco
Phase 2 Recruiting
NCT03016091 2025-02-18
A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
Rabin Medical Center
Phase 2 Terminated